The Effect of Citalopram on Gene Expression Profile of Alzheimer Lymphocytes

Antidepressants are widely used in the treatment of mood disorders associated with dementia, however little information is available on their effect at the molecular level. In certain neurodegenerative disorders, such as in Alzheimer's disease, lymphocytes have been used to assess mirror changes that thought to occur in the brain. Gene expression profiles of lymphocytes from Alzheimer patients have been shown to differ from that seen with controls. To address this issue in light of antidepressant treatment, we used lymphocytes derived from Alzheimer's disease patients and control individuals to assess the impact of the selective serotonine reuptake inhibitor citalopram on gene expression using a cDNA microarray representing 3200 distinct human genes. Sequences that are differentially regulated after treatment with citalopram were identified and categorized based on similarities in biological functions. This analysis revealed that the overexpression of genes in control and Alzheimer white blood cells by citalopram are implicated in cell survival. Apart from this, citalopram did not markedly alter genes involved in other molecular functions in control cells. In contrast, alteration of genes implicated in ionic currents, cell-adhesion, immune mechanism, and adrenergic functions, were also observed in Alzheimer lymphocytes. The expression of genes of Alzheimer lymphocytes by citalopram is modulated differently which may correlate with the pathology.     

Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment

The therapeutic effect of a course of antidepressant treatment is believed to involve a cascade of neuroadaptive changes in gene expression leading to increased neural plasticity. Because glutamate is linked to mechanisms of neural plasticity, this transmitter may play a role in these changes. This study investigated the effect of antidepressant treatment on expression of the vesicular glutamate transporters, VGLUT1-3 in brain regions of the rat. Repeated treatment with fluoxetine, paroxetine or desipramine increased VGLUT1 mRNA abundance in frontal, orbital, cingulate and parietal cortices, and regions of the hippocampus. Immunoautoradiography analysis showed that repeated antidepressant drug treatment increased VGLUT1 protein expression. Repeated electroconvulsive shock (ECS) also increased VGLUT1 mRNA abundance in regions of the cortex and hippocampus compared to sham controls. The antidepressant drugs and ECS did not alter VGLUT1 mRNA abundance after acute administration, and no change was detected after repeated treatment with the antipsychotic agents, haloperidol and chlorpromazine. In contrast to VGLUT1, the different antidepressant treatments did not commonly increase the expression of VGLUT2 or VGLUT3 mRNA. These data suggest that a course of antidepressant drug or ECS treatment increases expression of VGLUT1, a key gene involved in the regulation of glutamate secretion.     

Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice

Objective: To study the prevalence of xerostomia in an English population, attending general dental practice and relate it to age. medication and gender. Design Study: Cross‐sectional. Setting: Five General Dental Practices in Merseyside, North of England. Subjects: 1,103 adult patients attending for routine dental care. Intervention : Questionnaire administered by dentists. Main Outcome Measures: Age, gender, systemic medication, reported oral dryness. Results: 1,103 patients (654 females) were recruited, of whom 427 (39%) were aged 60 years or older, 26% of patients reported taking medication. The overall prevalence of xerostomia was 12.7% (males‐10.3%, females 14.4%). Age. medication and female gender were found to be significant risk factors for xerostomia, using logistic regression analysis. Conclusions: The prevalence of xerostomia (12.7%) in an English population was lower than reported in previous North American and Swedish studies. Medication was a significant risk factor for xerostomia and a better predictor of risk status, than either age or gender.     

Lessons learned from placebo groups in antidepressant trials

This comprehensive review provides an overview about placebo and nocebo phenomena in antidepressant trials. Improvements in the placebo groups may partly be explained through methodological issues such as natural course of depression and regression to the mean, but also fundamentally reflect investigators' and participants' expectations. A meta-analysis by our group of 96 randomized placebo-controlled trials showed large placebo responses to antidepressant medication. Moderator analyses revealed substantially larger placebo responses in observer ratings compared with self-report. Effect sizes in observer ratings showed strong increase with publication year while this effect was not found for patients' self-ratings. This reflects the strong influence of investigators' expectations. The analysis of 'nocebo effects', e.g. adverse effects in placebo groups of antidepressant trials also confirms the impact of expectations: nocebo symptoms reflected the typical side-effect patterns expected in the drug group, with higher symptoms rates in the placebo groups of tricyclic antidepressant trials compared with placebo groups of trials testing selective serotonin reuptake inhibitors. While the placebo response seems to be similar for women and men, gender differences were found for nocebo rates. In the conclusion, we discuss potential implications for clinical trial designs and argue for interventions aimed at optimizing positive expectations of treatment benefit while minimizing the impact of adverse effects.     

Characterization of electroencephalographic and biochemical responses at 5‐HT promoting drug‐induced onset of serotonin syndrome in rats

Many psychotropic substances used either for medications or illicit recreational purposes are able to produce an increase in extracellular serotonin (5HT) in the CNS. 5HT is well known to improve mood; however, only when the levels of its release are in an appropriate range. Excessive 5HT is harmful, and will generally result in serotonin syndrome. To date, clinical diagnosis of serotonin syndrome relies exclusively on observation of symptoms because of a lack of available laboratory tests. The goal of this study was to characterize the onset of the syndrome using laboratory settings to determine excessive 5HT‐evoked neurological abnormalities. Experiments were carried out in rats with the syndrome being elicited by three groups of 5HT‐promoting drugs: (i) (±)‐3,4‐methylenedioxymethamphetamine (MDMA); (ii) a combination of the monoamine oxidase inhibitor clorgyline with the 5HT precursor 5‐hydroxytryptophan; (iii) clorgyline combined with the serotonin‐selective reuptake inhibitor paroxetine. The onset of the syndrome was characterized by electroencephalography (EEG), tremor, and brain/plasma 5HT tests. We found that a mild syndrome was associated with reduced EEG amplitudes while a severe syndrome strongly with seizure‐like EEG activity and increased tremor activity. The occurrence of the syndrome was confirmed with microdialysis, showing excessive 5HT efflux in brain dialysate and the increased concentration of unbound 5HT in the plasma. Our findings suggest that the syndrome onset can be revealed with EEG recording, measurements of tremor activity and changes of unbound 5HT concentration in the plasma.     

The Circadian Rhythm of Plasma Thyrotropin in Depression and Recovery

The 24-hr patterns of plasma thyrotropin have been observed in 12 endogenous depressed patients in both depressed and recovered states and in 13 normal subjects. A clear circadian rhythm was detected in controls with high values at night. In depression, the circadian rhythm was altered with amplitude reduction and blunted nocturnal secretion, abnormalities particularly relevant in bipolar patients. This flattened profile could be linked to the blunted response of TSH to TRH administration reported in depressed patients. Normal nyctohemeral patterns have been restored after recovery. These chronobiological abnormalities as well as their normalization under antidepressant drugs seem to be similar to those reported for various parameters (e.g. temperature, Cortisol, etc) in depression which could support the chronobiological hypothesis for affective disorders.     

The presence of conifer resin decreases the use of the immune system in wood ants

Abstract.  1. Wood ants ( Formica paralugubris ) incorporate large amounts of solidified conifer resin into their nest, which reduces the density of many bacteria and fungi and protects the ants against some detrimental micro-organisms. By inducing an environment unfavourable to pathogens, the presence of resin may allow workers to reduce the use of their immune system.
2. The present study tested the hypothesis that the presence of resin decreases the immune activity of wood ants. Specifically, three components of the humoral immune defences of workers kept in resin-rich and resin-free experimental nests (antibacterial, lytic, and prophenoloxidase activities) were compared.
3. The presence of resin was associated with reduced bacterial and fungal densities in nest material and with a small decrease in worker antibacterial and lytic activities. The prophenoloxidase activity was very low in all workers and was not affected by the presence of resin.
4. These results suggest that collective medication with resin reduces pathogen pressure, which in turn decreases the use of the inducible part of the immune system. More generally, the use of plant secondary compounds might be an efficient and economical way to fight pathogens.     

Apelin receptor(APJ)拮抗剂F13A对小鼠抑郁样行为的影响及起效时间*

目的:明确apelin receptor(APJ)拮抗剂F13A对小鼠抑郁样行为的影响及起效时间。方法:实验小鼠随机分成对照组(Control),F13A组(F13A)和氯胺酮组(ketamine),每组9只,对照组小鼠腹腔注射生理盐水(10 ml/kg,ip)+侧脑室注射生理盐水(每职1μl,i.c.v),F13A组小鼠腹腔注射生理盐水(10 ml/kg,ip)+侧脑室注射F13A(6 μg/μl,i.c.v),氯胺酮组小鼠腹腔注射氯胺酮(10 ml/kg, 2 mg/ml,ip)+侧脑室注射生理盐水(1μl,i.c.v);实验分三批进行,第一批实验在注射后30 min,进行第一次强迫游泳测试(FST1),FST1后24 h进行第二次强迫游泳测试(FST2);第二批实验在注射后30 min进行第一次自发活动测试(LMT1),LMT1前24 h进行自发活动习惯化,LMT1后24 h进行第二次自发活动测试(LMT2);第三批实验注射后30 min进行FST1,FST1前24 h进行强迫游泳应激(FSS),FST1后24 h进行第二次强迫游泳测试(FST2)。 结果:与对照组比较,在无FSS时,氯胺酮组小鼠不动时间显著性减少(P﹤0.01),而F13A组小鼠无明显变化;在FST2中,F13A组小鼠不动时间显著性增加(P﹤0.01),而氯胺酮组小鼠无显著性差异;在LMT1和LMT2中各组小鼠活动度均无显著性差异;在经历FSS后,在FST1中氯胺酮组、F13A组小鼠不动时间均显著性减少(P﹤0.01);在FST2中,F13A组小鼠的不动时间显著性减少(P﹤0.05),而氯胺酮组小鼠无显著性差异(P＞0.05)。结论:APJ受体拮抗剂F13A在强迫游泳测试中发挥快速起效(30 min)且持久作用(24 h)的抗抑郁样潜力,并且这种作用可能与应激有关。     

Regulation of β1-Adrenergic Receptor mRNA and Ligand Binding by Antidepressant Treatments and Norepinephrine Depletion in Rat Frontal Cortex

Abstract: The number of β₁-adrenergic receptor (β₁AR) binding sites is decreased by chronic antidepressant treatments, including electroconvulsive seizure (ECS) and imipramine, whereas administration of agents that deplete norepinephrine (NE) increases the number of β₁AR binding sites in cerebral cortex. The present study was carried out to examine the influence of these treatments on levels of β₁ AR mRNA in frontal cortex to study the molecular mechanisms that underlie the regulation of β₁ ARs in brain. Levels of β₁ AR mRNA were measured by RNase protection analysis using a riboprobe derived from rat β₁AR cDNA, and the levels of βAR binding were measured using the nonselective ligand [³H]CGP-12177. Studies to verify the specificity of the RNase protection assay revealed that the distribution of β₁AR mRNA was in agreement with the reported distribution of β₁AR ligand binding: Levels of β₁AR mRNA were highest in cerebral cortex or frontal cortex, intermediate in neostriatum, hippocampus, lung, and heart, and lowest in cerebellum, kidney, and liver. Chronic ECS treatment (once daily for 10 days) significantly decreased levels of βAR ligand binding and resulted in a corresponding, time-dependent down-regulation of β₁AR mRNA levels in frontal cortex. However, imipramine administration regulated levels of β₁AR mRNA in a biphasic manner, with treatments for 7–14 days increasing and treatments for 18–21 days decreasing levels of β₁AR mRNA in frontal cortex. In contrast, levels of [³H]CGP-12177 ligand binding were decreased at all time points examined (3–21 days). The influence of NE depletion, using the neurotoxin 6-hydroxy-dopamine (6-OHDA), on levels of β₁AR mRNA was also examined. Three days after 6-OHDA treatment, levels of [³H]CGP-12177 ligand binding were not altered, but 7–14 days after neurotoxin treatment, levels of ligand binding were significantly increased. In contrast, 3–9 days after 6-OHDA treatment, levels of β₁AR mRNA were significantly decreased, and 14 days after treatment, levels of β₁AR mRNA returned to control values. The results demonstrate that β₁AR mRNA and ligand binding are regulated in parallel by ECS treatment but that levels of receptor mRNA are regulated in a complex manner by imipramine or 6-OHDA treatments, not predicted by changes in ligand binding.     

Block of the human ether-a-go-go-related gene (hERG) K channel by the antidepressant desipramine

Desipramine is a tricyclic antidepressant for psychiatric disorders that can induce QT prolongation, which may lead to torsades de pointes. Since blockade of cardiac human ether-a-go-go-related gene (hERG) channels is an important cause of acquired long QT syndrome, we investigated the acute effects of desipramine on hERG channels to determine the electrophysiological basis for its pro-arrhythmic potential. We examined the effects of desipramine on the hERG channels expressed in Xenopus oocytes using two-microelectrode voltage-clamp techniques. Desipramine-induced concentration-dependent decreases in the current amplitude at the end of the voltage steps and hERG tail currents. The IC₅₀ for desipramine needed to block the hERG current in Xenopus oocytes decreased progressively relative to the degree of depolarization. Desipramine affected the channels in the activated and inactivated states but not in the closed states. The S6 domain mutations, Tyr-652 located in the S6 domain of the hERG channel reduced the potency of the channel block by desipramine more than a mutation of Phe-656 in the same region. These results suggest that desipramine is a blocker of the hERG channels, providing a molecular mechanism for the arrhythmogenic side effects during the clinical administration of desipramine.